Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc.

Cardiol Therapeutics ( ($TSE:CRDL) ) has shared an update. On September 23, 2026, Cardiol Therapeutics reported that it had reached the original 11...

Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone

Cardiol Therapeutics ( ($TSE:CRDL) ) has provided an update. Cardiol Therapeutics has raised over USD $7 million through the exercise of outstandin...

Cardiol Therapeutics Bolsters Cash Runway with $7 Million Warrant Exercise Ahead of Phase III Data

Cardiol Therapeutics ( ($TSE:CRDL) ) has issued an announcement. Cardiol Therapeutics said on Sept. 10, 2026, that it has filed a preliminary short...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRDL	$1.72	-0.80%	184.70K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRDL	$1.72	-0.8%	184.70K
3
4
5
6

CRDL

Get Cardiol Therapeutics Inc. Data in Excel

Get Cardiol Therapeutics Inc. Data in Excel